# LifeMD, Inc.: Form 10-Q for the period ended Sep 30, 2013

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q
- Filed: 2013-11-14
- Accepted by EDGAR: Nov 14, 2013, 16:13 ET
- Period: 2013-09-30
- Accession: 0001144204-13-061835
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000114420413061835/v358889_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000114420413061835/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-07-01 to 2013-09-30 | $94.7k | us-gaap:Revenues |
| Revenue | 9 months, 2013-01-01 to 2013-09-30 | $647.8k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-07-01 to 2013-09-30 | $17.5k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2013-01-01 to 2013-09-30 | $124.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2013-07-01 to 2013-09-30 | $77.2k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2013-01-01 to 2013-09-30 | $523.7k | us-gaap:GrossProfit |
| Operating income | 3 months, 2013-07-01 to 2013-09-30 | −$168.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2013-01-01 to 2013-09-30 | −$259.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-07-01 to 2013-09-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 9 months, 2013-01-01 to 2013-09-30 | $0 | us-gaap:InterestExpense |
| Net income | 3 months, 2013-07-01 to 2013-09-30 | −$139.4k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2013-01-01 to 2013-09-30 | −$196.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-07-01 to 2013-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2013-01-01 to 2013-09-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2013-01-01 to 2013-09-30 | −$112.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2013-09-30 | $46.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-09-30 | $178.0k | us-gaap:AssetsCurrent |
| Total assets | at 2013-09-30 | $293.0k | us-gaap:Assets |
| Current liabilities | at 2013-09-30 | $217.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-09-30 | $252.2k | us-gaap:Liabilities |
| Shareholders' equity | at 2013-09-30 | $40.8k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,650 characters.

### Safe Harbor Declaration

### Overview

We manufacture, distribute and sell natural immune support products. We believe, based on testing and analysis conducted on our behalf, that our beta glucans derived from yeast are superior to other beta glucans. Beta glucans are a natural extract that has been shown through testing and analysis and scientific research to support the immune system. Our core nutraceutical and cosmetic product lines consist of yeast beta glucans in oral and topical applications. Our beta glucan products and manufacturing processes are protected by patents and trade secrets and are compliant with current GMPs. Yeast beta glucans are classified as GRAS (generally recognized as safe) by the FDA. Historically, we have sold our products primarily on a word-of-mouth basis through distributors and our website as standalone product lines, as well as business-to-business as dietary supplement and a cosmetic enhancement, and as a feed-additive for animal use. As of 2011, we began exiting this lower-margin market for feed-additive products. Our sales and marketing efforts going forward are concentrated on our oral and topical-use products for healthcare professionals, distributors and direct-to-consumer sales.

Significant factors that we believe could affect our operating results are (i) marketing and advertising expenses; (ii) protection of our intellectual property rights; and (iii) imposition of more stringent government regulations of our products.

Our marketing strategy is to promote sales of our oral and topical-use products, which constitute our core business as we shift from low-margin, feed-additive product sales. We believe that we are well positioned to capitalize on our development of proprietary and patented products and can now focus on commercializing sales on a more meaningful, global basis. We expect that a significant component of our selling, general and administration expenses going forward will consist of marketing and advertising expenses to increase our sales. The primary components of our marketing and advertising expenses may include online sales promotions through our website, trade advertising, direct marketing to nutraceutical companies and industry associations, consumer research and search engine and digital advertising. We expect our selling, general and administrative expenses to increase in absolute dollars as we incur increased costs related to our marketing strategy and growth of our business. These costs, along with the additional costs resulting from our operations as a public reporting company, could impact our future operating profitability.

On February 1, 2013, we hired a Chief Marketing Officer, the first such position in the Company’s history. We are planning to introduce new products that leverage our proprietary knowledge and intellectual property. Though there can be no assurance of success, we believe the tools are in place to execute on our marketing plan.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached a favorable settlement. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us.

Our manufacturing processes are compliant in the U.S. with current cGMPs and our yeast beta glucan products are all natural. Further, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, including reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have limited operating capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. While we believe that we will begin to generate increased sales, it is likely that we will require additional operating capital. Until we are in a position to obtain such capital from revenues to meet our normal business obligations, the Company will have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that the Company will be successful in its endeavors to raise additional capital.

### Results of Operations

### Three Months Ended September 30, 2013, Compared to the Three Months Ended September 30, 2012

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2013 $% of Sales |  | 2012 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 94,676 | - | 152,115 |  |
| Cost of sales | 17,475 | 18.5% | 53,854 | 35.4% |
| Gross profit | 77,201 | 81.5% | 98,261 | 64.6% |
| Operating expenses | (245,867) | (259.7)% | (261,901) | (172.2)% |
| Loss from operations | (168,666) | (178.2)% | (163,641) | (107.6)% |
| Other income | 25,000 | 26.4% | - | -% |
| Income tax benefit | 4,300 | 4.5% | 4,300 | 2.8% |
| Net loss | (139,366) | (147.2)% | (159,341) | (104.8)% |

Sales for the third quarter of 2013 were $94,676, a decrease of 38% from $152,115 for the same period in 2012. Our sales decreased as we exhausted our inventory on hand while focusing on rebranding our existing products and building additional inventory, raw materials and finished products, for sales. We took possession of this additional inventory in the first week of November.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales decreased 68% to $17,475 in the third quarter of 2013 compared to $53,854 for the same period in 2012. The decrease in cost of sales as a percentage of sales in 2012 compared to 2011 resulted primarily from our decrease in sales, and reduction in lab and other manufacturing costs.

Gross profit decreased 21% to $77,201in the third quarter of 2013 compared to $98,261 for the same period in 2012. The increase in gross profit as a percentage of sales from 65% in 2012 to 81% in 2013 was a result of a reduction in lab and other manufacturing costs.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Operating expenses decreased 6% to $245,867, in the third quarter of 2013 compared to $261,901 for the same period in 2012. General and administration expense increased by 45% to $123,572 due to work performed to set up our new online store, printing new labels in connection with the rebranding of our products and fees related to trade marking our rebranded products. Compensation and related expenses decreased by 2% to $102,166 in 2103, compared to $104,668 in 2012, due primarily to a reduction in stock based compensation. Professional fees significantly decreased 72% to $20,129 in 2013, compared to $71,827 in 2012, as a result of decreased legal fees.

Other income increased by $25,000 in 2013 due to the timing of license fee receipts.

Our net loss for the third quarter of 2013 was $139,366 compared to net loss of $159,341 for the same period in 2012, a decrease of $19,975 or 13%. Net loss as a percentage of sales was 147% in the third quarter of 2013 compared to net loss as a percentage of sales of 105% for the same period in 2012.

### Nine Months Ended September 30, 2013, Compared to the Nine Months Ended September 30, 2012

|  | 2013 $% of Sales |  | 2012 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 647,837 |  | 558,218 |  |
| Cost of sales | 124,181 | 19.2% | 190,778 | 34.2% |
| Gross profit | 523,656 | 80.8% | 367,440 | 65.8% |
| Operating expenses | (783,264) | (120.9)% | (782,615) | (140.2)% |
| Loss from operations | (259,608) | (40.1)% | (415,175) | (74.4)% |
| Other income | 50,000 | 7.7% | 31,161 | 6.0% |
| Interest (expense) | - | -% | (3,371) | (1.0)% |
| Income tax benefit | 12,900 | 2.0% | 12,900 | 2.3% |
| Net loss | (196,708) | (30.4)% | (374,485) | (67.1)% |

Sales for the nine months ended September 30, 2013 were $647,837, an increase of 16% from $558,218 for the same period in 2012. The increase in sales was attributable to increased demand for our topical-use products during the first and second quarter of 2013. Sales to our major customer amounted to $515,565 in 2013 compared to $427,073 in 2012.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales decreased 35% to $124,181 in the nine months ended September 30, 2013, compared to $190,778 for the same period in 2012. The decrease in cost of sales as a percentage of sales resulted primarily from a reduction in lab and other manufacturing costs.

Gross profit increased 43% to $523,656 in the nine months ended September 30, 2013, compared to $367,440 for the same period in 2012. Our gross profit as a percentage of sales increased from 66% in 2012 to 81% in 2013 due to our large increase in sales in the first half of the year and our reduction in lab and other manufacturing costs.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Operating expenses increased slightly by 1% in the nine months ended September 30, 2013, to $783,264 compared to $782,615 for the same period in 2012. General and administration expense increased by 8% to $298,953 in the nine months ended September 30, 2013, compared to $227,630 in the same period in 2012. Compensation and related expenses increased by 15% to $380,154 due primarily to the retention of a chief marketing officer, the first such position in the Company’s history. Professional fees decreased 41% to $104,157 as a result of decreased legal fees.

Other income amounted to $50,000 for the nine months ended September 30, 2013 compared to $31,161 for the same period in 2012. The increase is due primarily to the timing of license fee receipts.

Our net loss for the nine months ended September 30, 2013 was $196,708 compared to net loss of 374,485 for the same period in 2012, a decrease of $177,777 or 47%. Net loss as a percentage of sales was 30% for the nine months ended September 30, 2013 compared to net loss as a percentage of sales of 67% for the same period in 2012.

### Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We have limited operating capital and intend to meet our liquidity requirements, including purchase of raw materials and the expansion of our business, primarily through cash flow provided by operations. Historically, we also have funded operations through loans and advances from our directors and officers and offerings of equity securities. In 2012 and 2011, we raised $345,883 and $193,500, respectively, through sales of our common stock in private placements, as well as the exercising of stock options. During 2013 we raised $50,000 through the exercise of stock options. We may seek additional financing in the form of loans from banks or our directors and officers, or funds raised through future offerings of our equity or debt, if and when we determine such offerings are required. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness could increase our debt service obligations and cause us to be subject to restrictive operating and financial covenants.

We had net working capital (deficit) of $(39,475) at September 30, 2013, resulting in a decrease of $109,506 from net working capital of $70,031 at September 30, 2012. The ratio of current assets to current liabilities was .8 to 1 at September 30, 2013.

The following is a summary of cash provided by or used in each of the indicated types of activities during the nine months ended September 30, 2013 and 2012:

| Cash provided by (used in): | 2013 | 2012 |
| --- | ---: | ---: |
| Operating activities | $(112,478) | (165,473) |
| Financing activities | 60,200 | 295,154 |

Net cash flow used in operating activities was $112,478 for the nine months ended September 30, 2013, compared to net cash flow used in operating activities of $165,473 for the same period in 2012. The decrease in net cash outflow in operating activities was attributable primarily to our selling products we held in inventory that were produced in prior quarters.

Net cash flows provided by financing activities was $60,200 in 2013 and consisted of $50,000 from the exercise of stock options, and $10,200 from a director of the Company.

Net cash flows provided by financing activities in 2012 was $295,154 and consisted of $313,383 from private placement sales of our common stock and $32,500 for the exercise of stock options offset by $50,729 in repayment of notes payable.

### Private Placements

In a series of private placement transactions in the six months ended June 30, 2012, we issued 1,843,428 shares of our common stock and 3-year warrants to purchase 914,106 shares of our common stock at $0.40 per share to accredited investors at $0.17 per unit for $313,383.

In a series of private placement transactions in 2011, we issued (i) 621,053 shares of our common stock at $0.2286 per share for $142,000 and (ii) 302,941 shares of our common stock and 3-year warrants to purchase 151,500 shares of our common stock at $0.40 per share to accredited investors at $0.17 per unit for $51,500.

### Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. During the year ended December 31, 2012, notes payable due to officer and other related individuals totaling $50,729 were repaid and the balance of notes payable and amounts due to officer, aggregating $311,443, were converted to common stock. Interest expense on notes payable amounted to $3,371 for the year ended December 31, 2012.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. At September 30, 2013, we included $114,000 in accounts payable and accrued expenses relating to this royalty agreement, with the remaining commitment under the royalty agreement at approximately $75,000. In connection with this agreement, $38,000 in royalties has been paid as of September 30, 2013. Our President, Mr. McLaughlin, has a 60% interest in the royalties paid under the agreement and has voluntarily deferred payments due without interest until we have the financial wherewithal to pay such royalties.

### Going Concern

Based on the Company's cash balance at September 30, 2013 and projected cash needs for the remainder of 2013 and into 2014, management estimates that it will need to raise additional capital to cover operating and capital requirements. Management plans on raising the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.

## Controls and procedures

As filed, 2,717 characters.

### Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. Our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy once funds are available; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2013, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 145 characters.

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012.

Filed Nov 14, 2013.
Source: SEC EDGAR, the filing index for accession 0001144204-13-061835. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
